TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma AB has announced an extra general meeting scheduled for October 13, 2025, to discuss significant changes in its corporate structure, including amendments to the articles of association and a reverse share split. These proposed changes are aimed at optimizing the company’s capital structure and enhancing its financial flexibility, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB operates in the biopharmaceutical industry, focusing on the development and commercialization of biosimilar drugs. The company aims to provide affordable and accessible treatments by leveraging its expertise in biosimilar development.
Average Trading Volume: 14,023,811
Technical Sentiment Signal: Sell
Current Market Cap: SEK685.4M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.